2022
Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial
Ware J, Boughton CK, Allen JM, Wilinska ME, Tauschmann M, Denvir L, Thankamony A, Campbell FM, Wadwa RP, Buckingham BA, Davis N, DiMeglio LA, Mauras N, Besser REJ, Ghatak A, Weinzimer SA, Hood KK, Fox DS, Kanapka L, Kollman C, Sibayan J, Beck RW, Hovorka R, Consortium D, Hovorka R, Acerini C, Thankamony A, Allen J, Boughton C, Dovc K, Dunger D, Ware J, Musolino G, Tauschmann M, Wilinska M, Hayes J, Hartnell S, Slegtenhorst S, Ruan Y, Haydock M, Mangat J, Denvir L, Kanthagnany S, Law J, Randell T, Sachdev P, Saxton M, Coupe A, Stafford S, Ball A, Keeton R, Cresswell R, Crate L, Cripps H, Fazackerley H, Looby L, Navarra H, Saddington C, Smith V, Verhoeven V, Bratt S, Khan N, Moyes L, Sandhu K, West C, Wadwa R, Alonso G, Forlenza G, Slover R, Towers L, Berget C, Coakley A, Escobar E, Jost E, Lange S, Messer L, Thivener K, Campbell F, Yong J, Metcalfe E, Allen M, Ambler S, Waheed S, Exall J, Tulip J, Buckingham B, Ekhlaspour L, Maahs D, Norlander L, Jacobson T, Twon M, Weir C, Leverenz B, Keller J, Davis N, Kumaran A, Trevelyan N, Dewar H, Price G, Crouch G, Ensom R, Haskell L, Lueddeke L, Mauras N, Benson M, Bird K, Englert K, Permuy J, Ponthieux K, Marrero-Hernandez J, DiMeglio L, Ismail H, Jolivette H, Sanchez J, Woerner S, Kirchner M, Mullen M, Tebbe M, Besser R, Basu S, London R, Makaya T, Ryan F, Megson C, Bowen-Morris J, Haest J, Law R, Stamford I, Ghatak A, Deakin M, Phelan K, Thornborough K, Shakeshaft J, Weinzimer S, Cengiz E, Sherr J, Van Name M, Weyman K, Carria L, Steffen A, Zgorski M, Sibayan J, Beck R, Borgman S, Davis J, Rusnak J, Hellman A, Cheng P, Kanapka L, Kollman C, McCarthy C, Chalasani S, Hood K, Hanes S, Viana J, Lanning M, Fox D, Arreaza-Rubin G, Eggerman T, Green N, Janicek R, Gabrielson D, Belle S, Castle J, Green J, Legault L, Willi S, Wysham C. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. The Lancet Digital Health 2022, 4: e245-e255. PMID: 35272971, DOI: 10.1016/s2589-7500(22)00020-6.Peer-Reviewed Original ResearchConceptsClosed-loop groupInsulin pump therapyType 1 diabetesControl groupBaseline HbAUsual carePump therapyClosed-loop insulin deliverySuboptimal glucose controlPediatric diabetes centersKey inclusion criteriaClosed-loop insulin delivery systemPrimary endpointBlock randomisationDiabetes CenterGlucose controlInsulin delivery systemsInclusion criteriaPrimary analysisTherapyInsulin deliveryMonthsG pumpHbADiabetes
2020
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri R, Battelino T, Laffel LM, Slover RH, Schatz D, Weinzimer SA, Dovc K, Danne T, Phillip M. Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nature Medicine 2020, 26: 1380-1384. PMID: 32908282, DOI: 10.1038/s41591-020-1045-7.Peer-Reviewed Original ResearchConceptsType 1 diabetesInsulin dose adjustmentPhysician armDose adjustmentAcademic diabetes centerInsulin pump settingsPrimary efficacy measureSevere adverse eventsTarget glucose rangeInsulin pump therapyNon-inferiority trialArtificial intelligence-based decision support systemAdverse eventsInsulin titrationDiabetes CenterEfficacy measuresPump therapyPercentage of timePercentage of readingsGlucose levelsSix monthsContinuous glucose monitoring devicesDiabetesInsulin pumpGlucose monitoring devices1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System
COMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System. Diabetes 2020, 69 DOI: 10.2337/db20-1298-p.Peer-Reviewed Original ResearchMeals/snacksDiabetes careHybrid closed-loop insulin delivery systemParents of youthMental burdenClosed-loop insulin delivery systemBoehringer Ingelheim PharmaceuticalsSanofi UST1D durationDiabetes CenterCarbohydrate intakeSpouse/partnerInsulin delivery systemsDietary restrictionJanssen PharmaceuticalsArtificial pancreas systemsYoung adultsInsulin deliverySpeakers bureauCareIntakeCGM usersAge 10National InstituteEli Lilly998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents
ROETHKE L, COMMISSARIAT P, FINNEGAN J, VOLKENING L, BUTLER D, DASSAU E, WEINZIMER S, LAFFEL L. 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents. Diabetes 2020, 69 DOI: 10.2337/db20-998-p.Peer-Reviewed Original ResearchDiabetes careT1D durationInsulin pumpType 1 diabetesBoehringer Ingelheim PharmaceuticalsSanofi USDiabetes CenterDifferent treatment situationsSpouse/partnerInsulin delivery systemsCare burdenGlucose levelsJanssen PharmaceuticalsT1DArtificial pancreas systemsDiabetesEmotional burdenParents of youthYoung adultsSpeakers bureauCareAge 10Emotional distressNational InstituteUnderwent content analysis